Zelluna Immunotherapy is a company pioneering the development of allogeneic T cell receptor (TCR) guided natural killer (NK) cell immunotherapies for the treatment of solid cancers. The company is developing a portfolio of tumor specific TCRs to guide NK cells with the aim to induce cancer responses that are safe, efficient and durable. For more info please visit www.zelluna.com
View Top Employees from Zelluna Immunotherapy| Website | http://www.zelluna.com |
| Revenue | $6.4 million |
| Employees | 27 (20 on RocketReach) |
| Founded | 2016 |
| Address | 64 Ullernchausséen, Oslo, Oslo 0379, NO |
| Phone | 468594788 |
| Technologies |
HTML,
Google Analytics,
reCAPTCHA
+4 more
(view full list)
|
| Industry | Biotechnology Research, Business Services General, Health Care, Business Services, Medical, Pharmaceutical |
| SIC | SIC Code 873 Companies, SIC Code 87 Companies |
| NAICS | NAICS Code 541 Companies, NAICS Code 5417 Companies, NAICS Code 541713 Companies, NAICS Code 54171 Companies, NAICS Code 54 Companies |
Looking for a particular Zelluna Immunotherapy employee's phone or email?
Zelluna Immunotherapy Questions
The Zelluna Immunotherapy annual revenue was $6.4 million in 2023.
Namir Hassan is the CEO of Zelluna Immunotherapy.
20 people are employed at Zelluna Immunotherapy.
Zelluna Immunotherapy is based in Oslo, Oslo.
The NAICS codes for Zelluna Immunotherapy are [541, 5417, 541713, 54171, 54].
The SIC codes for Zelluna Immunotherapy are [873, 87].
Top Zelluna Immunotherapy Employees
-
4
-
45+
-
2
-
2
-
2
-
ViewPranav Oberoi
Group Leader, Process Development at Zelluna Immunotherapy
Frankfurt, Hesse, Germany2
Related Companies
